eFT508 + avelumab

eFT508 + avelumab is a **combination therapy under clinical investigation for multiple cancers, especially microsatellite stable (MSS) colorectal cancer**. eFT508 (tomivosertib) is a potent, selective, oral inhibitor of the kinases MNK1 and MNK2, which block translation of oncogenic and immunosuppressive proteins, aiming to activate anti-tumor immune responses by downregulating proteins such as PD-1, PD-L1, and LAG-3. Avelumab is a monoclonal anti-PD-L1 checkpoint inhibitor (commercially known as Bavencio) that prevents tumor cells from evading immune detection by blocking PD-L1, restoring T-cell mediated cytotoxicity. The combination is designed to overcome resistance to checkpoint inhibitors and improve outcomes in patients who have not responded adequately to immunotherapy alone[1][2][5][8].

Brand names

Bavencio

Other names

eFT508 + Bavenciotomivosertib + avelumab